Ahmad Gharehbaghian: Visiting the Alborz Provincial Blood Transfusion Center
Ahmad Gharehbaghian, Managing Director at Iranian Blood Transfusion Organization, shared a post on LinkedIn:
“This morning, I had the opportunity to visit the Alborz Provincial Blood Transfusion Center in Karaj to meet with the good, hardworking, and capable colleagues working across its various departments.
These visits serve several purposes:
- first, to get to know the colleagues personally—who are active in over 280 blood centres nationwide; and to express my gratitude and appreciation for all their efforts;
- second, to become closely acquainted with the operational processes at the centers, from donor recruitment right through to the distribution of blood and its products;
- third, to listen to the concerns, challenges, criticisms, and suggestions of the staff; and finally, to inspect the technical facilities and equipment firsthand and discuss technical matters with the team.
Fortunately, the Alborz Provincial Blood Transfusion Center has not only been successful and distinguished in supplying blood and blood products for the province itself, but it also provides commendable support to other blood transfusion centers across the country, including those in Gilan, Mazandaran, and Tehran.
It is only fitting that I sincerely express my gratitude to each and every one of the esteemed and capable colleagues at the Alborz Provincial Blood Transfusion Center for all their impactful work.”
Stay updated with Hemostasis Today.
-
Sep 9, 2026, 15:10Pablo Corral: Is the Lp(a) Hypothesis Wrong?
-
Sep 9, 2026, 14:54Agnes Kisakye: Expanding Point-of-Care Ultrasound and Surgical Interventions for Hemophilia in Uganda
-
Sep 9, 2026, 14:52Jan Sloves: Addressing Diagnostic and Treatment Variability in Pelvic-Origin Varicose Veins
-
Sep 9, 2026, 14:48The French Care Pathway for Gene Therapy in Haemophilia B – CRH French Reference Center for Hemophilia Lyon
-
Sep 9, 2026, 14:43David McIntosh: The Ethics of Plasma Donation
-
Sep 9, 2026, 14:42Thirunavukkarasu Angappan: Factor VIII and IX Didn’t Get Viral-Safety Rules Until the 1980s
-
Sep 9, 2026, 14:30Alejandro González Veliz: 2026 ESC Guidelines Expand Cardiac Rehabilitation Beyond Post-Event Recovery
-
Sep 9, 2026, 13:59Natalie Arnold: Biomarkers and the Hidden Burden of CHD
-
Sep 9, 2026, 13:11Ron DePinho: A Negative Trial Does Not Repudiate Inflammation as a Cardiovascular Target